Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Cancer Prev Res (Phila). 2021 Nov 8;15(2):129–138. doi: 10.1158/1940-6207.CAPR-21-0399

Fig. 4.

Fig. 4.

SSUV responses in nevi. A, Sunburn cells were quantitated from H&E sections of UV-treated nevi from the cohorts receiving placebo (n=28), 81 mg daily ASA (ASA-81, n=32), and 325 mg daily ASA (ASA-325, n=31). Few or no sunburn cells were observed in unirradiated nevi. Bars represent mean and error bars represent SEM. Analyses did not reveal significant differences between SSUV-treated nevi in the ASA-81 (P= 0.8) or ASA-325 (P=0.55) and placebo cohorts. NS, not significant. B, CD3 expression in unirradiated and SSUV-treated nevi (left panel). Percent changes in SSUV-induced CD3 count for each group (right panel). Bars represent mean and error bars represent SEM. There were no significant differences in CD3 between unirradiated or SSUV-treated nevi in either the ASA-81 (P=0.37 and 0.45, respectively) or ASA-325 (P=0.60 and 0.75, respectively) cohort compared to placebo. Similarly, paired analyses comparing unirradiated and SSUV-treated nevi did not demonstrate significant differences in SSUV-induced CD3 for either the ASA-81 (P=0.13) or ASA-325 (P=0.53) cohort compared to placebo. NS, not significant. C, 8-OG. Percent cells staining for 8-OG in unirradiated and SSUV-treated nevi within each of the indicated cohorts. There were no significant differences in 8-OG between unirradiated or SSUV -treated nevi in either the ASA-81 (P=0.48 and 0.10, respectively) or ASA-325 (P=0.29 and 0.17, respectively) cohort compared to placebo (left panel). Paired analyses comparing unirradiated and SSUV-treated nevi did not demonstrate significant differences in SSUV -induced 8-OG for either the ASA-81 (P=0.07) or ASA-325 (P=0.37) cohort compared to placebo (right panel). D, CPD. Percent cells staining for CPD in unirradiated and SSUV-treated nevi within each of the indicated cohorts. There were no significant differences in CPD between unirradiated or SSUV-treated nevi in either the ASA-81 (P=0.46 and 0.25, respectively) or ASA-325 (P=0.45 and 0.47, respectively) cohort compared to placebo (left panel). Paired analyses comparing unirradiated and SSUV-treated nevi did not demonstrate significant differences in SSUV-induced CPD for either the ASA-81 (P=0.25) or ASA-325 (P=0.39) cohort compared to placebo (right panel).